Novo Nordisk is raising its annual forecast as weight loss pill sales beat expectations
The Danish drugmaker expects 2026 adjusted sales and operating profit to range from a 2% decline to 2% growth at constant rates
The Danish drugmaker expects 2026 adjusted sales and operating profit to range from a 2% decline to 2% growth at constant rates